NCT00028301已完成3 期
A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus Lopinavir/Ritonavir(LPV/RTV), Each in Combination With Two Nucleosides in Subjects Who Have Experienced Virologic Failure With Prior Protease Inhibitor-Containing HAART Regimen(s)
Bristol-Myers Squibb97 个研究点 分布在 14 个国家开始时间: 2001年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 97
研究概览
简要总结
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
详细描述
The study is designed to determine the metabolic changes, antiviral activity, safety, and tolerability of atazanavir as compared to LPV/RTV, each in combination with 2 nucleosides, over the initial 24 weeks, with a final analysis at 48 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are receiving a PI-containing highly active antiretroviral therapy (HAART) for at least 12 weeks.
- •Have a viral load of 1,000 or more copies/ml within 4 weeks of screening and within 4 weeks prior to randomization.
- •Have 2 CD4 cell counts of 50 or more cells/mm3 at least 96 hours apart and within 4 weeks before randomization.
- •Are at least 16 years old.
- •Have a documented virologic response to at least 1 HAART regimen.
- •Have phenotypic sensitivity to at least 2 of the following: ddl, d4T, ZDV, 3TC, ABC.
- •Have phenotypic sensitivity to atazanavir and LPV/RTV.
- •Use effective barrier methods of birth control.
- •Will be available for 48 weeks.
排除标准
- •Patients will not be eligible for this study if they:
- •Have taken 2 or more PIs and had virologic failure.
- •Have taken atazanavir or LPV/RTV.
- •Have an HIV-related infection (within 30 days) or any medical condition requiring treatment at the time of enrollment.
- •Have had acute hepatitis in the 30 days prior to study entry.
- •Have received certain drugs within 3 months of study start or expect to need them at time of enrollment.
- •Abuse alcohol or drugs in a way that would interfere with the study.
- •Have very bad diarrhea within 30 days prior to study entry.
- •Are pregnant or breast-feeding.
- •Have a history of hemophilia.
- •Use lipid-lowering drugs (within the previous 30 days).
- •Have cardiomyopathy or symptoms of other heart disease.
- •Cannot take medicine by mouth.
- •Have any other condition that would interfere with the study.
- •Have pancreatitis, if choosing ddI as part of NRTI pair.
- •Have bilateral peripheral neuropathy at time of screening, if choosing ddI or or d4T as part of the NRTI pair.
研究者
研究点 (97)
Loading locations...
相似试验
已完成
3 期
A Study to Compare Two Anti-HIV Drug CombinationsHIV InfectionsNCT00002447Hoffmann-La Roche146
已完成
4 期
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With AtriplaHIV-1NCT02547844Hospital Universitari Vall d'Hebron Research Institute30
已完成
不适用
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIVHIV InfectionsNCT00006441National Institute of Allergy and Infectious Diseases (NIAID)398
终止
2 期
Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected PatientsHIV InfectionsNCT00122577French National Agency for Research on AIDS and Viral Hepatitis50
已完成
3 期
The Late Presenter Treatment Optimisation StudyHIV/AIDSNCT03696160NEAT ID Foundation447